Technologies
PDF


WARF: P100068US02

Vitamin D Analog “N-23” for Cancer Prevention and Treatment


INVENTORS -

Hector DeLuca, Pawel Grzywacz, Lori Plum, Margaret Clagett-Dame

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a vitamin D analog known as N-23 that is potentially useful as a chemotherapeutic agent.
OVERVIEWThe hormonally active form of vitamin D, known as calcitriol or 1,25 dihydroxyvitamin D3, has shown promise for treating diseases ranging from osteoporosis to cancer to psoriasis. However, the hormone mobilizes calcium from bones and increases intestinal absorption of dietary calcium. Effective therapeutic concentrations can lead to hypercalcemia; a condition characterized by elevated blood calcium levels, alterations in mental status, muscle weakness and calcification of soft tissues and organs such as the heart and kidneys. Therefore, a need exists for non-calcemic compounds that provide desirable therapeutic effects without causing dose-limiting hypercalcemia.
THE INVENTIONUW–Madison researchers have developed a novel vitamin D analog, (20S,22E)-methylene-19-nor-22-ene-1α,25-dihydroxyvitamin D3, also known as N-23. This compound binds the vitamin D receptor with the same affinity as the native hormone but is more potent in causing cellular differentiation and increasing expression of the 24-hydroxylase gene. It also is less active than calcitriol in causing intestinal calcium transport. It potentially may be developed into a useful anticancer agent.
APPLICATIONS
  • Cancer prevention and treatment, particularly for colorectal, breast or prostate cancer
KEY BENEFITS
  • More potent than calcitriol in causing cell differentiation and gene transcription
  • Less likely to cause dose-limiting hypercalcemia than calcitriol
  • Can be administered in many forms
Contact Information
For current licensing status, please contact Rafael Diaz at rdiaz@warf.org or 608-960-9847.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.